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with low levels of bleeding in acute coronary syndromes has been
shown to be far smaller (100 mg daily) than used in the Chan
study (2). Second, patients with infective endocarditis presenting
with emboli have been documented to have excessive bleeding
when given high-dose antiplatelet and fibrinolytic therapy after
acute coronary embolism (3). Third, Chan et al. imply that
vegetations in infective endocarditis are mostly platelet derived.
Platelet activation can be independent of cyclo-oxygenase activity,
and therefore aspirin may not inhibit platelet activation when other
routes of platelet activation are stimulated (4,5). We therefore
agree with the conclusion that high-dose aspirin is not indicated
for infective endocarditis, but we would like to see further studies
of other antiplatelet or anticoagulant drugs before negating the use
of all these treatments for the prophylaxis of emboli in infective
endocarditis. Clearly, in cases of coronary emboli, development of
primary angioplasty and development of percutaneous clot removal
devices mean that new technologies may afford further treatment
options in this life-threatening scenario (6,7).
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REPLY
The optimal dose of aspirin in vascular diseases remains contro-
versial. Although low aspirin doses (100 mg daily) have potential
advantages over higher doses, a recent meta-analysis has shown
that in patients at high risk for vascular events, there was a similar
reduction of events over a dose range of 75 to 1500 mg daily. The
risk of major bleeding was similar in all aspirin doses equal to or
less than 325 mg daily (1). Thus, we believe that the dose of aspirin
used in our study (325 mg daily) is appropriate. The concern of
excessive bleeding with a combined use of aspirin and fibrinolytic
therapy is valid, but this does not apply to our study because none
of our patients received fibrinolytic therapy. It is possible that other
antiplatelet agents may have salutary effects in patients with
infective endocarditis. Nonetheless, our study underscores that
these patients have a high risk for excessive bleeding—14.5% major
or minor bleeding cases in our patients on placebo—which needs
to be considered in any future studies examining the role of
antiplatelet agents in this clinical setting.
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